Compare IDEXX Laboratories, Inc. (IDXX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs DENTSPLY SIRONA Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: IDEXX Laboratories, Inc. is far larger — about 23.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| IDXX | XRAY | |
|---|---|---|
Market Cap | $40.43B | $1.73B |
Volume | 692,164 | 6,198,582 |
Sector | Health | Health |
52-Week High | $766.68 | $14.68 |
52-Week Low | $504.70 | $8.52 |
Typical Hold Time | 46 Days | 72 Days |
Enterprise Value | $41.32B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
